LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Torin1 | 0.12 | uM | LJP6 | 3 | O17 | 72 | hr | 1657 | 2144 | 5505 | 0.3894 | 0.1264 |
BT-20 | Torin2 | 0.12 | uM | LJP5 | 1 | I23 | 72 | hr | 1657 | 1474 | 5505 | 0.2677 | -0.0478 |
BT-20 | Torin2 | 0.12 | uM | LJP5 | 2 | I23 | 72 | hr | 1657 | 1486 | 5505 | 0.2699 | -0.0446 |
BT-20 | Torin2 | 0.12 | uM | LJP5 | 3 | I23 | 72 | hr | 1657 | 1608 | 5505 | 0.2921 | -0.0129 |
BT-20 | Tozasertib | 0.12 | uM | LJP5 | 1 | B17 | 72 | hr | 1657 | 2087 | 5505 | 0.3791 | 0.1116 |
BT-20 | Tozasertib | 0.12 | uM | LJP5 | 2 | B17 | 72 | hr | 1657 | 1737 | 5505 | 0.3155 | 0.0206 |
BT-20 | Tozasertib | 0.12 | uM | LJP5 | 3 | B17 | 72 | hr | 1657 | 2114 | 5505 | 0.3840 | 0.1186 |
BT-20 | Trametinib | 0.12 | uM | LJP5 | 1 | P23 | 72 | hr | 1657 | 4137 | 5505 | 0.7514 | 0.6443 |
BT-20 | Trametinib | 0.12 | uM | LJP5 | 2 | P23 | 72 | hr | 1657 | 4629 | 5505 | 0.8408 | 0.7722 |
BT-20 | Trametinib | 0.12 | uM | LJP5 | 3 | P23 | 72 | hr | 1657 | 4481 | 5505 | 0.8139 | 0.7337 |
BT-20 | TWS119 | 0.12 | uM | LJP5 | 1 | M05 | 72 | hr | 1657 | 4928 | 5505 | 0.8951 | 0.8499 |
BT-20 | TWS119 | 0.12 | uM | LJP5 | 2 | M05 | 72 | hr | 1657 | 5544 | 5505 | 1.0070 | 1.0100 |
BT-20 | TWS119 | 0.12 | uM | LJP5 | 3 | M05 | 72 | hr | 1657 | 5571 | 5505 | 1.0119 | 1.0170 |
BT-20 | Vemurafenib | 0.12 | uM | LJP5 | 1 | C17 | 72 | hr | 1657 | 5644 | 5505 | 1.0251 | 1.0360 |
BT-20 | Vemurafenib | 0.12 | uM | LJP5 | 2 | C17 | 72 | hr | 1657 | 5658 | 5505 | 1.0277 | 1.0396 |
BT-20 | Vemurafenib | 0.12 | uM | LJP5 | 3 | C17 | 72 | hr | 1657 | 5848 | 5505 | 1.0622 | 1.0890 |
BT-20 | Withaferin A | 0.12 | uM | LJP5 | 1 | G17 | 72 | hr | 1657 | 5479 | 5505 | 0.9952 | 0.9931 |
BT-20 | Withaferin A | 0.12 | uM | LJP5 | 2 | G17 | 72 | hr | 1657 | 5523 | 5505 | 1.0031 | 1.0045 |
BT-20 | Withaferin A | 0.12 | uM | LJP5 | 3 | G17 | 72 | hr | 1657 | 5390 | 5505 | 0.9790 | 0.9699 |
BT-20 | Withaferin A | 0.12 | uM | LJP6 | 1 | G17 | 72 | hr | 1657 | 5294 | 5505 | 0.9616 | 0.9450 |
BT-20 | Withaferin A | 0.12 | uM | LJP6 | 2 | G17 | 72 | hr | 1657 | 5233 | 5505 | 0.9505 | 0.9291 |
BT-20 | Withaferin A | 0.12 | uM | LJP6 | 3 | G17 | 72 | hr | 1657 | 5539 | 5505 | 1.0061 | 1.0087 |
BT-20 | WYE-125132 | 0.12 | uM | LJP6 | 1 | L11 | 72 | hr | 1657 | 2654 | 5505 | 0.4821 | 0.2589 |
BT-20 | WYE-125132 | 0.12 | uM | LJP6 | 2 | L11 | 72 | hr | 1657 | 2550 | 5505 | 0.4632 | 0.2319 |
BT-20 | WYE-125132 | 0.12 | uM | LJP6 | 3 | L11 | 72 | hr | 1657 | 2455 | 5505 | 0.4459 | 0.2072 |